Goserelin (Zoladex®)

Common name: Goserelin
Brand name: Zoladex®
 

What is Goserelin?

Goserelin is a hormonal therapy used to treat advanced prostate cancer by blocking the production or action of luteinizing hormone releasing hormone (LHRH) which reduces the levels of testosterone in the body.

Goserelin is used:
  • in the palliative treatment of patients with hormone-dependent advanced prostate cancer.
  • in combination with non-steroidal anti-androgens and radiation therapy for treating locally advanced prostate cancer.
  • as an adjuvant hormone therapy to external beam irradiation for locally advanced prostate cancer.


How is Goserelin administered?

Goserelin is administered by subcutaneous injection.


What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received goserelin. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Breast tenderness
  • Changes to mood
  • Decreased sex drive (low libido)
  • Fatigue
  • Hot flashes
  • Impotence
  • Nausea / vomiting
  • Osteoporosis (weakened bones)
  • Rashes
  • Sore joints
  • Weight gain
 

Is Goserelin covered in my province or territory?*

Goserelin is covered by all provincial/territorial drug programs.


*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=19055
Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More

Rocco Rossi to wrap up successful 5-year tenure as Prostate Cancer Canada CEO

September 7, 2017 - TORONTO, ON - With mixed emotions, longstanding Prostate Cancer Canada (PCC) President and CEO, Rocco Rossi, formally announced today that his time leading the organization will officially come to a close as of December 31, 2017.
More


Click here for news archive